ArticleCureus2025
Challenges of Treatment-Resistant Bipolar Depression in the Elderly: A Case Study of Successful Modafinil Augmentation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-resistant bipolar depression (TRBD) poses a significant challenge, especially in older adults, where comorbidities and medication tolerability limit therapeutic options. Modafinil, a wakefulness-promoting agent, has shown promise as an adjunctive treatment in mood disorders. We report the case of a 74-year-old man with long-standing bipolar disorder and multiple comorbidities, including chronic kidney disease (CKD) and cerebellar ataxia, who presented with persistent depressive symptoms despite multiple pharmacological trials. Conventional treatments, including lithium, antipsychotics, and antidepressants, were either ineffective or poorly tolerated. Modafinil was introduced as an augmentative strategy, starting at 100 mg daily and titrated to 200 mg. Over 16 weeks, the patient demonstrated marked improvement in mood, motivation, and wakefulness, with his Montgomery-Åsberg Depression Rating Scale (MADRS) score reduced by 23 points (70%) from 29 to 6. No adverse effects or mood destabilization were observed. This case highlights the potential utility of modafinil in TRBD, particularly in elderly patients with limited pharmacological options. Its broad neurochemical activity and tolerability profile make it a candidate for augmentation in selected cases. While caution is warranted due to potential risks, this report supports further exploration of modafinil in adult populations with TRBD. Modafinil may be a safe and effective adjunct in treatment-resistant bipolar depression, especially when conventional therapies are contraindicated. Its use may extend beyond elderly populations to adults with similar clinical challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.